AGEN.NASDAQAgenus INC

Form 4: Agenus Inc. CEO Garo Armen Receives Stock in Lieu of Cash Salary

Sentiment:

SEC Form 4 Filing


Agenus Inc. CEO Garo Armen received 4,700 shares of common stock in lieu of cash salary for the pay period ending May 16, 2025, at a price of $3.48 per share.

Summary

  • Garo H. Armen, CEO of Agenus Inc., received 4,700 shares of Agenus common stock on May 16, 2025, as compensation in lieu of cash salary.
  • The stock was issued at a price of $3.48 per share, which was the closing price of Agenus common stock on that date.
  • These shares are fully vested upon issuance, in accordance with the company's 2019 Equity Incentive Plan.
  • Armen also indirectly owns 31,298 shares through IRA accounts and 28,950 shares as trustee and general partner.
  • The transaction was reported in a Form 4 filing with the SEC on May 20, 2025.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The CEO taking salary in stock could be seen as a positive sign of confidence, but it's not a major event.

Positives

  • The CEO's decision to take salary in stock may signal confidence in the company's future performance.
  • The issuance of fully vested shares aligns the CEO's interests with those of the shareholders.

Industry Context

This type of compensation arrangement, where executives receive stock in lieu of cash, is not uncommon in the biotech industry, particularly for companies focused on long-term growth and innovation. It aligns executive compensation with shareholder value and encourages long-term decision-making.

Comparison to Industry Standards

  • Stock-based compensation is a common practice among biotech companies, especially for executive roles.
  • Comparing Agenus's executive compensation structure with companies like Gilead Sciences, Amgen, or Biogen would provide a broader context.
  • These companies often use a mix of salary, stock options, and restricted stock units to incentivize their executives.

Stakeholder Impact

  • Shareholders may view the CEO accepting stock in lieu of cash as a positive sign of alignment with their interests.
  • Employees may see this as a sign of the company's commitment to conserving cash.

Key Dates

DateDescription
05/16/2025Date of transaction: Garo Armen received stock in lieu of cash salary.
05/20/2025Date of Form 4 filing with the SEC.

Keywords

Agenus, Garo Armen, Stock, Salary, Form 4, Beneficial Ownership, Equity Incentive Plan

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.